MedPath

Safety and Efficacy of Drug Combinations Against Trichuris Trichiura

Registration Number
NCT01050452
Lead Sponsor
DBL -Institute for Health Research and Development
Brief Summary

This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of albendazole (ALB), mebendazole (MBD) and ivermectin (IVM) separately, and ALB and MBD each in combination with IVM in the treatment of Trichuris trichiura in children aged 5-14 years.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
750
Inclusion Criteria
  • Those who are enrolled in class one to six
  • Are infected with T. trichiura
  • Whose parent consent and who are willing to participate
Exclusion Criteria
  • Those with acute and chronic diseases other than T. trichiura
  • Those with a history of any serious adverse drug reactions

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1albendazolealbendazole treatment
2mebendazolemebendazole treatment
3ivermectinivermectin treatment
4albendazole + ivermectinalbendazole + ivermectin treatment
5mebendazole + ivermectinmebendazole + ivermectin treatment
Primary Outcome Measures
NameTimeMethod
Record adverse reactions6 weeks
Secondary Outcome Measures
NameTimeMethod
Efficacy of treatment6 weeks

Trial Locations

Locations (1)

Vector Control Division

🇺🇬

Kampala, Uganda

Vector Control Division
🇺🇬Kampala, Uganda

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.